Holy Name Press Releases

Advanced Accelerator Applications Announces First Administration of NETSPOT™ at Holy Name Medical Center

August 3, 2016

Advanced Accelerator Applications S.A. (NASDAQ:AAAP) ("AAA" or "the Company"), an international specialist in Molecular Nuclear Medicine (MNM), today announced the first administration of NETSPOT™, a product recently approved by the U.S. Food and Drug Administration ("FDA") for the preparation of gallium Ga 68 dotatate for injection, for the localization of somatostatin receptor positive neuroendocrine tumors ("NETs") in adult and pediatric patients using Positron Emission Tomography ("PET") at Holy Name Medical Center ("Holy Name") in Teaneck, NJ.

Michael Maron, President and Chief Executive Officer of Holy Name commented, "In our commitment to provide the latest advancements in cancer diagnosis, I’m proud to say Holy Name is the first in the U.S. to offer a new standard of care for our patients. As in all cancer care, earlier detection can be life-saving and almost always improves the quality of life for patients."

Stefano Buono, Chief Executive Officer of AAA said, "We are very excited to bring NETSPOT™, a widely anticipated new imaging product to patients in the U.S. We believe NETSPOT™ offers superior sensitivity and accuracy compared to previously available diagnostics for NET patients. In a clinical study, NETSPOT demonstrated the ability to change management decisions regarding patients in 71% of cases previously imaged with Octreoscan.1 Saving just one patient from futile surgery can improve the treatment experience, as well as generate cost savings greater than the cost of providing a year’s worth of NETSPOT™ injections to every NET patient treated in the same hospital! We are proud to contribute to the introduction of pharmaceutical products that improve patient care, while decreasing healthcare costs."

Lynn Reiman the first patient to receive a PET scan with NETSPOT™ declared, "NET patients like me typically struggle for years, trying to get an accurate diagnosis because of the nature of this hard-to-detect cancer. Beyond the frustration of living with an undetected disease, are the health consequences of delayed treatment. I’ve had this disease for eight years, and throughout that time, Dr. Condemi has treated my symptoms because he knew the disease was there, but he couldn't target the location of the cancerous cells with the usual method of detection, which was an Octreoscan – until now. I’m thrilled to see better diagnostic tools becoming available and am honored to be the first U.S. patient to receive this scan."

Giuseppe Condemi, MD, PhD, Medical Director of the Carcinoid Center at Holy Name stated, "NETSPOT™ is a significant improvement over existing diagnostic tools and will enable us to more accurately stage and better manage patients. This is the biggest challenge oncologists face with NET patients, due to the complexity of localizing these malignancies."

Jacqueline Brunetti, M.D., Medical Director of Radiology at Holy Name observed, "NETSPOT™ alleviates patient burden by providing a faster procedure, lower radiation exposure and eliminating the need for bowel cleansing; while increasing our ability to handle more patients with faster scan acquisition and reduced imaging time. Most importantly, NETSPOT™ is a dramatic leap forward in detecting NETs and has greatly enhanced sensitivity versus older techniques."

NETSPOT™ is currently available in the U.S. in two forms: As a kit for reconstitution using a Ga 68 generator, and as NETSPOT™ Injection, a ready-to-use dose delivered from a local radiopharmacy in selected metropolitan areas. AAA has partnered with four radiopharmacies in the U.S. to facilitate availability of NETSPOT™ nationally, including Zevacor Pharma Inc., that delivered the NETSPOT™ injection to Holy Name Medical Center.